CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 13 enrolled
Drug / intervention
Brimonidine +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03959176
NCT03959176Phase 4Completed
CompareCT.gov

The Effect of Brimonidine on Intraocular Pressure When Dilating Routine Patients, Pressure Control and Pupil Effects

Wake Forest University Health Sciences·interventional·Posted May 22, 2019·Updated Feb 1, 2024

In Brief

A Phase 4 clinical trial evaluating Brimonidine, Tropicamide, and 1 other intervention for Intraocular Pressure. Completed, enrolled 13 participants across 1 site.

Detailed Summary

This study will evaluate whether pre-treating patients with Brimonidine 0.2% before and/or after dilating the pupils will help to control the changes in intraocular pressure often seen when using dilating drops. The study will also evaluate the effects of different sequences of administering dilating drops along with Brimonidine on pupil size and reactivity.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIntraocular Pressure
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2020202120222023202420252026
First PostedMay 22, 2019
Enrollment StartJul 20, 2019
Primary CompletionJul 20, 2019
TodayJul 2, 2026
Enrollment to primary: 0 daysPosted 7.1 years ago

Interventions

Brimonidinedrug

2 drops administered once in the left eye in both study arms

Tropicamidedrug

1 drop administered at two different times points in both eyes in both study arms

Phenylephrine Ophthalmic Productdrug

1 drop administered at two different time points in both eyes in both study arms